Robert J. Spiegel M.D., FACP
Director, Board of Directors
Dr. Spiegel became a Director for Sucampo in January 2015. He currently serves as Chief Medical Officer of PTC Therapeutics and is the President and Founder of Spiegel Consulting. Dr. Spiegel previously served as Chief Medical Officer at Schering-Plough Research Institute from 1998 to 2009, where he held positions of increasing responsibility since joining the company in 1983. At Schering-Plough, Dr. Spiegel was involved in the successful filing of over 30 New Drug Applications.
Dr. Spiegel is currently an Associate Professor at Weill Cornell Medical Center. He serves on the Board of Directors and on the advisory committees of a number of companies, including clinical-stage biotechnology companies Edge Therapeutics and Geron Corporation, as well as Avior Computing Corporation, a risk and compliance management software company, and Warburg Pincus, a global private equity investment institution.
Dr. Spiegel earned a bachelor’s degree, cum laude, from Yale University and a medical degree from the University of Pennsylvania.
Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of specialized medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products – AMITIZA, its lead product, and RESCULA – and a late-stage pipeline of product candidates in clinical development for orphan disease areas. VTS-270 is a mixture of 2-hydroxypropyl-B-cyclodextrins with a specific compositional fingerprint that has been granted orphan designation in the U.S. and Europe and is in a pivotal Phase 2/3 clinical trial for the treatment of Niemann-Pick Disease Type C-1. Sucampo has an option for the North American rights to CPP1- x/sulindac, which is in Phase 3 development for the treatment of familial adenomatous polyposis and has been granted orphan drug designation in the U.S. A global company, Sucampo is headquartered in Rockville, Maryland, and has operations in Japan and Switzerland.